X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs STRIDES PHARMA SCIENCE - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA STRIDES PHARMA SCIENCE AUROBINDO PHARMA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 13.6 15.9 85.7% View Chart
P/BV x 3.0 0.9 315.1% View Chart
Dividend Yield % 0.4 0.5 81.8%  

Financials

 AUROBINDO PHARMA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
STRIDES PHARMA SCIENCE
Mar-18
AUROBINDO PHARMA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs8091,147 70.5%   
Low Rs504642 78.5%   
Sales per share (Unadj.) Rs281.1317.2 88.6%  
Earnings per share (Unadj.) Rs41.47.8 527.2%  
Cash flow per share (Unadj.) Rs50.925.1 203.1%  
Dividends per share (Unadj.) Rs2.502.00 125.0%  
Dividend yield (eoy) %0.40.2 170.3%  
Book value per share (Unadj.) Rs199.4274.3 72.7%  
Shares outstanding (eoy) m585.8889.50 654.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.32.8 82.8%   
Avg P/E ratio x15.9114.0 13.9%  
P/CF ratio (eoy) x12.935.7 36.1%  
Price / Book Value ratio x3.33.3 101.0%  
Dividend payout %6.025.5 23.7%   
Avg Mkt Cap Rs m384,63080,058 480.4%   
No. of employees `00017.32.5 691.3%   
Total wages/salary Rs m21,3084,341 490.9%   
Avg. sales/employee Rs Th9,500.711,325.8 83.9%   
Avg. wages/employee Rs Th1,229.41,731.4 71.0%   
Avg. net profit/employee Rs Th1,397.9280.1 499.2%   
INCOME DATA
Net Sales Rs m164,66628,394 579.9%  
Other income Rs m1,020941 108.4%   
Total revenues Rs m165,68629,334 564.8%   
Gross profit Rs m37,7183,965 951.2%  
Depreciation Rs m5,5801,540 362.2%   
Interest Rs m7771,962 39.6%   
Profit before tax Rs m32,3801,403 2,307.6%   
Minority Interest Rs m310-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m8,18397 8,409.8%   
Profit after tax Rs m24,229702 3,450.9%  
Gross profit margin %22.914.0 164.0%  
Effective tax rate %25.36.9 364.4%   
Net profit margin %14.72.5 595.1%  
BALANCE SHEET DATA
Current assets Rs m121,87824,836 490.7%   
Current liabilities Rs m86,80618,993 457.0%   
Net working cap to sales %21.320.6 103.5%  
Current ratio x1.41.3 107.4%  
Inventory Days Days13071 183.0%  
Debtors Days Days68113 60.3%  
Net fixed assets Rs m81,03734,289 236.3%   
Share capital Rs m586895 65.5%   
"Free" reserves Rs m116,21823,651 491.4%   
Net worth Rs m116,80424,546 475.9%   
Long term debt Rs m4,51215,513 29.1%   
Total assets Rs m211,05265,437 322.5%  
Interest coverage x42.71.7 2,487.6%   
Debt to equity ratio x00.6 6.1%  
Sales to assets ratio x0.80.4 179.8%   
Return on assets %11.84.1 291.0%  
Return on equity %20.72.9 725.2%  
Return on capital %27.46.9 396.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,72715,697 514.3%   
Fx outflow Rs m34,700735 4,718.6%   
Net fx Rs m46,02714,962 307.6%   
CASH FLOW
From Operations Rs m19,5481,871 1,045.0%  
From Investments Rs m-19,5705,826 -335.9%  
From Financial Activity Rs m8,642-10,157 -85.1%  
Net Cashflow Rs m8,922-2,615 -341.2%  

Share Holding

Indian Promoters % 54.1 27.7 195.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 37.8 21.0%  
FIIs % 27.7 8.6 322.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 25.9 39.4%  
Shareholders   69,601 56,241 123.8%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   VENUS REMEDIES  ORCHID PHARMA LTD  SANOFI INDIA  TTK HEALTHCARE  PROCTER & GAMBLE HEALTH  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Witness Selling, Passenger Vehicles Sales Data, and Top Cues in Focus Today(Pre-Open)

India share markets witnessed selling pressure yesterday and ended their session deep in the red. At the closing bell yesterday, the BSE Sensex stood lower by 267 points (down 0.7%).

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Super investor Pulak Prasad is Buying Stocks Big Time...and You Should Too(The 5 Minute Wrapup)

Aug 9, 2019

Here's why the relentless correction in the Indian stock markets has not unnerved the big investors.

Interest Rates Are Low. Buy Solid Dividend Stocks Instead(The 5 Minute Wrapup)

Aug 13, 2019

The dividends paid by these stocks are helpful when interest rates are falling.

Smallcaps that Will Outperform in the Market Rebound(Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

Qatar is Rearing Cows...this is Good News for India

Aug 9, 2019

Qatar has turned around after the Saudi embargo. This is good news for India.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Aug 21, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - STRIDES PHARMA SCIENCE COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS